Special Issue

Nano-Drug Delivery Technologies for Cancer Immunotherapy

Message from the Guest Editors

We are pleased to invite you to contribute to a Special Issue of *Pharmaceutics* entitled "Nano-Drug Delivery Technologies for Cancer Immunotherapy". As a novel anti-tumor modality, cancer immunotherapy has made significant clinical progress in recent years by activating the body's immune function to target and efficiently eliminate cancer cells. Meanwhile, the use of nanotechnology for delivering cancer therapeutics has also achieved fruitful clinical translation: its main advantages lie in the abilities of nanocarriers to optimize drug distribution and provide a platform for multi-modal theranostics, realizing targeted and synergistic cancer therapies. This Special Issue aims to publish research or reviews on novel drug delivery nanotechnology (such as new nanomaterials, new nanodrug synthetic approaches, or optimized drug loading methods) for immunotherapeutic drugs, as well as the original anticancer mechanisms based on immunomodulatory nanoformulations. We look forward to receiving your contributions.

Guest Editors

Prof. Dr. Guangya Xiang

 School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China
 School of Pharmacy, Tongren Polytechnic College, Tongren 554300, China

Dr. Xiaojuan Zhang

Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiahang Road 118, Jiaxing 314001, China

Deadline for manuscript submissions

closed (30 November 2024)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/178884

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

